Literature DB >> 15012613

Central reassessment of GH concentrations measured at local treatment centers in children with impaired growth: consequences for patient management.

Berthold P Hauffa1, Nils Lehmann, Markus Bettendorf, Otto Mehls, Helmuth-Günther Dörr, Carl-Joachim Partsch, Hans P Schwarz, Nikolaus Stahnke, Heinz Steinkamp, Elfriede Said, Sabine Sander, Michael B Ranke.   

Abstract

OBJECTIVE: GH deficiency is diagnosed in children if serum GH fails to rise above a predefined cutoff value in response to at least two stimuli. Diagnostic decisions based on this testing are highly variable between centers and depend on the GH assays used. Considering the large spectrum of commercially available GH assays, we wanted to evaluate the agreement between assays, and to test whether assay-related variability of diagnostic decisions could be reduced by reassessment of peak GH concentrations in a reference center.
DESIGN: We reanalysed 699 peak GH serum samples obtained after GH testing of 382 children and adolescents from 19 centers using three reference assays and compared these results with those obtained with the local assays. A subgroup of 132 patients tested with the combination of insulin hypoglycemia test and arginine test was evaluated for changes in the assignment to the diagnostic group of GH deficiency.
RESULTS: The mean difference between methods ranged from 5.4 to 10.3 mU/l, slopes of the regression lines from 1.28 to 1.65. Significant non-linearity was detected in five of six assay comparisons, indicating that most assay results cannot be interconverted by the use of a factor. Overall agreement between reference and local assays was only moderate. Significant changes in diagnostic assignment occurred when different assays were used on the same patient (P<0.0001-P<0.0023). Based on GH remeasurement by one reference assay, 36 of 132 patients were categorized differently, with 35 patients changing into the GH-deficient group. Similar findings were obtained with the other reference assays.
CONCLUSIONS: To decrease variability in GH testing related to assays and cutoff values, we recommend nationwide reassessment of GH peak sera in reference centers. Decisions to treat GH deficiency should incorporate the reference center results.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15012613     DOI: 10.1530/eje.0.1500291

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  Application of Analyte Harvesting Nanoparticle Technology to the Measurement of Urinary HGH in Healthy Individuals.

Authors:  Alessandra Luchini; Davide Tamburro; Ruben Magni; Claudia Fredolini; Virginia Espina; Jaume Bosch; Enrico Garaci; Emanuel F Petricoin; Lance A Liotta
Journal:  J Sports Med Doping Stud       Date:  2012

Review 2.  Dilemmas of growth hormone treatment for GH deficiency and idiopathic short stature: defining, distinguishing, and deciding.

Authors:  Julia G Halas; Adda Grimberg
Journal:  Minerva Pediatr       Date:  2020-04-09       Impact factor: 1.312

Review 3.  Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences.

Authors:  Martin Bidlingmaier; Pamela U Freda
Journal:  Growth Horm IGF Res       Date:  2009-10-08       Impact factor: 2.372

Review 4.  Growth hormone variants: a potential avenue for a better diagnostic characterization of growth hormone deficiency in children.

Authors:  A E Rigamonti; M Bozzola; G Banfi; C Meazza; E E Müller; S G Cella
Journal:  J Endocrinol Invest       Date:  2012-10-01       Impact factor: 5.467

Review 5.  Growth hormone assays: current methodologies and their limitations.

Authors:  Martin Bidlingmaier; Christian J Strasburger
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

6.  Short Stature Diagnosis and Referral.

Authors:  Mohamad Maghnie; José I Labarta; Ekaterina Koledova; Tilman R Rohrer
Journal:  Front Endocrinol (Lausanne)       Date:  2018-01-11       Impact factor: 5.555

7.  Parathyroid hormone assay: problems and opportunities.

Authors:  Kevin J Martin; Esther A González
Journal:  Pediatr Nephrol       Date:  2007-05-22       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.